Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06271057

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Golcadomide (BMS-986369) Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Sponsor: Lymphoma Study Association

Conditions Diffuse Large B-cell Lymphoma Refractory Refractory High Grade B-Cell Lymphoma Refractory Primary Mediastinal Large B-Cell Lymphoma Refractory Transformed B-cell Non-Hodgkin Lymphoma

Interventions golcadomide

Updated 4 times since 2024 Last updated: Oct 8, 2024 Started: Jun 14, 2024 Primary completion: Jan 15, 2026 Completion: Oct 20, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Diffuse Large B-cell Lymphoma Refractory and Refractory High Grade B-Cell Lymphoma, this trial is actively recruiting participants. The trial is conducted by Lymphoma Study Association and has accumulated 4 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Nov 2024 — Present [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Nov 2024 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Mar 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lymphoma Study Association
The Lymphoma Academic Research Organisation

Data source: The Lymphoma Academic Research Organisation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Créteil, France , Dijon, France , La Tronche, France , Lille, France , Marseille, France , Montpellier, France , Nantes, France , Paris, France , Pessac, France , Rennes, France and 3 more locations